Corcept Therapeutics Faces Class Action Lawsuit Over Misleading FDA Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy CORT?
Source: Globenewswire
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics and its executives, alleging that misleading statements made between October 31, 2024, and December 30, 2025, resulted in significant investor losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept misled the market by asserting its lead product was nearing approval, despite receiving multiple warnings from the FDA about inadequate clinical data prior to its NDA submission, leading to investor misconceptions about the company's prospects.
- Stock Price Plummet: On December 31, 2025, Corcept's stock price collapsed from $70.20 to $34.80 following the announcement of a Complete Response Letter from the FDA, erasing over $3.6 billion in market value, reflecting extreme market disappointment in the company's future.
- Investor Action Call: Hagens Berman urges investors who purchased Corcept stock during the class period to contact the firm by April 21, 2026, to discuss their rights and potentially serve as lead plaintiffs in the lawsuit, emphasizing the importance of protecting their interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 41.870
Low
50.00
Averages
91.00
High
121.00
Current: 41.870
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action for Corcept Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, to apply as lead plaintiffs by April 21, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Corcept made false statements regarding the strong support from FDA for the NDA of relacorilant, while in reality, the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to significant risks.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, as many firms issuing notices lack actual litigation experience and may only act as intermediaries, potentially failing to effectively protect investors' rights.
See More
Corcept's Drug Application Rejected by FDA, Class Action Filed
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter declining to approve its New Drug Application for relacorilant, citing insufficient evidence of effectiveness, which led to a 50.42% drop in stock price to $34.80, severely impacting investor confidence.
- Stock Price Volatility: Following the FDA's rejection, Corcept's stock plummeted by $35.40 in a single day, reflecting a pessimistic market outlook on the company's future prospects and potentially exposing investors to significant losses.
- Class Action Initiated: Investors have filed a class action lawsuit due to the failure to disclose FDA concerns regarding the adequacy of the clinical development program during the Class Period from October 31, 2024, to December 30, 2025, which could harm the company's reputation and future financing capabilities.
- Legal Implications for Investors: Investors must file to be lead plaintiffs by April 21, 2026, indicating a crisis of trust in the company's management, which may lead to stricter regulatory scrutiny and legal challenges in the future.
See More
Corcept Faces Securities Class Action Lawsuit
- Deadline for Lawsuit: ClaimsFiler reminds investors that those who purchased Corcept Therapeutics (Nasdaq: CORT) shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: The lawsuit alleges that Corcept and certain executives failed to disclose material information during the class period, violating federal securities laws, particularly regarding the approval prospects of their new drug application, misleading investors about the company's potential.
- FDA Response Letter: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding its relacorilant NDA, stating it could not reach a favorable benefit-risk assessment without additional evidence of effectiveness, which directly impacted investor confidence.
- Stock Price Plunge: Following this news, Corcept's stock price plummeted by $35.40, or 50.4%, from a closing price of $70.20 on December 30, 2025, to $34.80 on December 31, 2025, reflecting a pessimistic outlook from the market regarding the company's future prospects.
See More
Pomerantz Files Class Action Against Corcept Therapeutics
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Corcept Therapeutics, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by April 21, 2026, to protect their interests.
- Adverse FDA Response: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant, indicating that the agency requires additional evidence of effectiveness, highlighting significant regulatory concerns about the drug's safety and efficacy.
- Stock Price Plunge: Following the unfavorable FDA news, Corcept's stock price plummeted by $35.40, or 50.4%, closing at $34.80 per share, reflecting a pessimistic outlook from the market regarding the company's future prospects and potentially undermining investor confidence.
- Legal Firm Background: Pomerantz LLP is a prominent class action law firm with over 85 years of experience in corporate, securities, and antitrust litigation, dedicated to fighting for the rights of victims of securities fraud, showcasing its deep expertise and influence in the legal field.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that April 21, 2026, is the critical deadline to apply as Lead Plaintiff in the pending securities class action, urging investors to submit their losses before this date to participate in the lawsuit.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose significant facts regarding its lead drug candidate, relacorilant, during its communications with the FDA, misleading investors about the company's prospects and confidence in the drug's approval.
- Market Crash Impact: Following the announcement on December 31, 2025, that Corcept received a Complete Response Letter from the FDA, the company's stock plummeted from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, severely impacting investor confidence.
- Data Flaw Allegations: The complaint highlights that despite explicit warnings from the FDA in 2024 and 2025 regarding the inadequacy of clinical data, Corcept continued to promote its Phase 3 trial results, indicating significant failures in the company's disclosure practices.
See More
Corcept Securities Class Action Reminder for Investors
- Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, or risk losing their right to claim.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, a 50.4% drop from $70.20 to $34.80, following the FDA's rejection of its new drug application, severely impacting investor confidence and the company's market capitalization.
- Legal Allegations Context: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA approval for a key product candidate.
- Law Firm's Role: Kahn Swick & Foti, LLC, a leading securities litigation firm, is reminding investors to pay attention to this case and offers legal consultation services to help investors understand their rights and potential compensation for economic losses.
See More
Reminder of Class Action for Corcept Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, to apply as lead plaintiffs by April 21, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Corcept made false statements regarding the strong support from FDA for the NDA of relacorilant, while in reality, the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to significant risks.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, as many firms issuing notices lack actual litigation experience and may only act as intermediaries, potentially failing to effectively protect investors' rights.
See More
Corcept's Drug Application Rejected by FDA, Class Action Filed
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter declining to approve its New Drug Application for relacorilant, citing insufficient evidence of effectiveness, which led to a 50.42% drop in stock price to $34.80, severely impacting investor confidence.
- Stock Price Volatility: Following the FDA's rejection, Corcept's stock plummeted by $35.40 in a single day, reflecting a pessimistic market outlook on the company's future prospects and potentially exposing investors to significant losses.
- Class Action Initiated: Investors have filed a class action lawsuit due to the failure to disclose FDA concerns regarding the adequacy of the clinical development program during the Class Period from October 31, 2024, to December 30, 2025, which could harm the company's reputation and future financing capabilities.
- Legal Implications for Investors: Investors must file to be lead plaintiffs by April 21, 2026, indicating a crisis of trust in the company's management, which may lead to stricter regulatory scrutiny and legal challenges in the future.
See More
Corcept Faces Securities Class Action Lawsuit
- Deadline for Lawsuit: ClaimsFiler reminds investors that those who purchased Corcept Therapeutics (Nasdaq: CORT) shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: The lawsuit alleges that Corcept and certain executives failed to disclose material information during the class period, violating federal securities laws, particularly regarding the approval prospects of their new drug application, misleading investors about the company's potential.
- FDA Response Letter: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding its relacorilant NDA, stating it could not reach a favorable benefit-risk assessment without additional evidence of effectiveness, which directly impacted investor confidence.
- Stock Price Plunge: Following this news, Corcept's stock price plummeted by $35.40, or 50.4%, from a closing price of $70.20 on December 30, 2025, to $34.80 on December 31, 2025, reflecting a pessimistic outlook from the market regarding the company's future prospects.
See More
Pomerantz Files Class Action Against Corcept Therapeutics
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Corcept Therapeutics, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by April 21, 2026, to protect their interests.
- Adverse FDA Response: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant, indicating that the agency requires additional evidence of effectiveness, highlighting significant regulatory concerns about the drug's safety and efficacy.
- Stock Price Plunge: Following the unfavorable FDA news, Corcept's stock price plummeted by $35.40, or 50.4%, closing at $34.80 per share, reflecting a pessimistic outlook from the market regarding the company's future prospects and potentially undermining investor confidence.
- Legal Firm Background: Pomerantz LLP is a prominent class action law firm with over 85 years of experience in corporate, securities, and antitrust litigation, dedicated to fighting for the rights of victims of securities fraud, showcasing its deep expertise and influence in the legal field.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that April 21, 2026, is the critical deadline to apply as Lead Plaintiff in the pending securities class action, urging investors to submit their losses before this date to participate in the lawsuit.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose significant facts regarding its lead drug candidate, relacorilant, during its communications with the FDA, misleading investors about the company's prospects and confidence in the drug's approval.
- Market Crash Impact: Following the announcement on December 31, 2025, that Corcept received a Complete Response Letter from the FDA, the company's stock plummeted from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, severely impacting investor confidence.
- Data Flaw Allegations: The complaint highlights that despite explicit warnings from the FDA in 2024 and 2025 regarding the inadequacy of clinical data, Corcept continued to promote its Phase 3 trial results, indicating significant failures in the company's disclosure practices.
See More
Corcept Securities Class Action Reminder for Investors
- Lawsuit Deadline: Investors must file lead plaintiff applications for the Corcept securities class action by April 21, 2026, concerning trades made between October 31, 2024, and December 30, 2025, or risk losing their right to claim.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, a 50.4% drop from $70.20 to $34.80, following the FDA's rejection of its new drug application, severely impacting investor confidence and the company's market capitalization.
- Legal Allegations Context: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA approval for a key product candidate.
- Law Firm's Role: Kahn Swick & Foti, LLC, a leading securities litigation firm, is reminding investors to pay attention to this case and offers legal consultation services to help investors understand their rights and potential compensation for economic losses.
See More
